These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21725053)

  • 21. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
    Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
    BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.
    Choi JR; Kim JO; Kang DR; Yoon SA; Shin JY; Zhang X; Roh MO; Hong HJ; Wang YP; Jo KH; Lee KS; Yun HJ; Oh YS; Yoo KD; Jeon HG; Lee YS; Kang TS; Park HJ; Chung MW; Kang JH
    J Hum Genet; 2011 Apr; 56(4):290-5. PubMed ID: 21326313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.
    Gong IY; Schwarz UI; Crown N; Dresser GK; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Wells PS; Kim RB; Tirona RG
    PLoS One; 2011; 6(11):e27808. PubMed ID: 22114699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Warfarin dosing and the promise of pharmacogenomics.
    Dumas TE; Hawke RL; Lee CR
    Curr Clin Pharmacol; 2007 Jan; 2(1):11-21. PubMed ID: 18690851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.
    Zhang W; Zhang WJ; Zhu J; Kong FC; Li YY; Wang HY; Yang YH; Wang C
    Pharmacogenomics; 2012 Feb; 13(3):309-21. PubMed ID: 22248286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
    Miyagata Y; Nakai K; Sugiyama Y
    Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Possible application of pharmacogenomics to warfarin therapy].
    Murata M
    Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
    N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
    King CR; Porche-Sorbet RM; Gage BF; Ridker PM; Renaud Y; Phillips MS; Eby C
    Am J Clin Pathol; 2008 Jun; 129(6):876-83. PubMed ID: 18480003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy.
    Luxembourg B; Schneider K; Sittinger K; Toennes SW; Seifried E; Lindhoff-Last E; Oldenburg J; Geisen C
    Thromb Haemost; 2011 Jan; 105(1):169-80. PubMed ID: 21057703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of warfarin pharmacogenetic testing in clinical practice.
    Tan GM; Wu E; Lam YY; Yan BP
    Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.